SI3233108T1 - Hitro delujoči pripravki inzulina - Google Patents

Hitro delujoči pripravki inzulina

Info

Publication number
SI3233108T1
SI3233108T1 SI201531823T SI201531823T SI3233108T1 SI 3233108 T1 SI3233108 T1 SI 3233108T1 SI 201531823 T SI201531823 T SI 201531823T SI 201531823 T SI201531823 T SI 201531823T SI 3233108 T1 SI3233108 T1 SI 3233108T1
Authority
SI
Slovenia
Prior art keywords
rapid
acting insulin
insulin compositions
compositions
acting
Prior art date
Application number
SI201531823T
Other languages
English (en)
Slovenian (sl)
Inventor
Michael Patrick Akers
Ranajoy Majumdar
Chi A. Nguyen
Chad D. Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3233108(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI3233108T1 publication Critical patent/SI3233108T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201531823T 2014-12-16 2015-12-09 Hitro delujoči pripravki inzulina SI3233108T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092407P 2014-12-16 2014-12-16
PCT/US2015/064744 WO2016100042A1 (en) 2014-12-16 2015-12-09 Rapid-acting insulin compositions
EP15817678.4A EP3233108B1 (en) 2014-12-16 2015-12-09 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
SI3233108T1 true SI3233108T1 (sl) 2022-05-31

Family

ID=55066806

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531823T SI3233108T1 (sl) 2014-12-16 2015-12-09 Hitro delujoči pripravki inzulina

Country Status (18)

Country Link
US (4) US9993555B2 (enExample)
EP (2) EP4108253A1 (enExample)
JP (5) JP6328855B2 (enExample)
AR (1) AR102869A1 (enExample)
CY (1) CY1125275T1 (enExample)
DK (1) DK3233108T3 (enExample)
ES (1) ES2911207T3 (enExample)
HR (1) HRP20220692T1 (enExample)
HU (1) HUE058764T2 (enExample)
LT (1) LT3233108T (enExample)
MA (1) MA41188B1 (enExample)
MD (1) MD3233108T2 (enExample)
PL (1) PL3233108T3 (enExample)
PT (1) PT3233108T (enExample)
RS (1) RS63174B1 (enExample)
SI (1) SI3233108T1 (enExample)
TW (1) TW201630622A (enExample)
WO (1) WO2016100042A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3518893A1 (en) 2016-09-29 2019-08-07 Arecor Limited Novel formulations
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
WO2018153506A1 (en) * 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.
KR20190140048A (ko) * 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193351A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277731B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2020186154A1 (en) * 2019-03-14 2020-09-17 The Regents Of The University Of California Methods and compositions for supporting renal health
US10639328B1 (en) * 2019-03-27 2020-05-05 College Of William & Mary Compositions and methods for reducing hyperglycemia and treating diabetes
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
AU2020351154A1 (en) * 2019-09-17 2022-03-31 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin formulations and methods of administration
WO2021081404A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
IL296090A (en) * 2020-03-02 2022-11-01 Thermalin Inc Compositions containing rapid-acting insulin analogues
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
DE3880346T2 (de) 1987-02-25 1993-07-29 Novonordisk As Insulinderivate.
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
PT1146896E (pt) 1999-01-26 2002-10-31 Lilly Co Eli Formulacoes monodispersas de analogo acilado e hexamerico insulina
AU779798C (en) 1999-11-15 2005-11-17 Hanamaraddi T. Gangal Dextrose and insulin fluid formulation for intravenous infusion
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ES2373660T3 (es) 2003-11-13 2012-02-07 Novo Nordisk A/S Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PL2319500T3 (pl) 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008013955A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
PT2612677E (pt) 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
US20120178675A1 (en) 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
MX341448B (es) 2011-06-17 2016-08-19 Halozyme Inc Metodos de infusion de insulina subcutanea continua con una enzima que degrada a hialuronano.
WO2012174478A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2013177565A1 (en) 2012-05-25 2013-11-28 Amylin Pharmaceuticals, Llc Insulin-pramlintide compositions and methods for making and using them
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
KR102351111B1 (ko) 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
US11123406B2 (en) 2021-09-21
PT3233108T (pt) 2022-05-05
ES2911207T3 (es) 2022-05-18
US20240238382A1 (en) 2024-07-18
HRP20220692T1 (hr) 2022-07-08
LT3233108T (lt) 2022-05-10
JP2018500314A (ja) 2018-01-11
AR102869A1 (es) 2017-03-29
WO2016100042A1 (en) 2016-06-23
MD3233108T2 (ro) 2022-09-30
JP6328855B2 (ja) 2018-05-23
PL3233108T3 (pl) 2022-06-20
RS63174B1 (sr) 2022-05-31
TW201630622A (zh) 2016-09-01
JP7159277B2 (ja) 2022-10-24
JP7093669B2 (ja) 2022-06-30
US20190231851A1 (en) 2019-08-01
MA41188B1 (fr) 2022-08-31
CY1125275T1 (el) 2024-12-13
US20160166695A1 (en) 2016-06-16
HUE058764T2 (hu) 2022-09-28
JP2025032126A (ja) 2025-03-11
JP2023011641A (ja) 2023-01-24
EP4108253A1 (en) 2022-12-28
MA41188A (fr) 2017-10-24
JP2018138578A (ja) 2018-09-06
US9993555B2 (en) 2018-06-12
EP3233108B1 (en) 2022-03-30
JP2021073187A (ja) 2021-05-13
US11872266B2 (en) 2024-01-16
US20220072105A1 (en) 2022-03-10
EP3233108A1 (en) 2017-10-25
DK3233108T3 (da) 2022-04-11

Similar Documents

Publication Publication Date Title
IL248350A0 (en) Fast-acting insulin preparations
PT3233108T (pt) Composições de insulina de atuação rápida
ZA201800511B (en) Rapid-acting insulin compositions
GB201410905D0 (en) Composition
GB201501859D0 (en) Composition
IL251703B (en) A pharmaceutical preparation with improved stability
SG11201704735WA (en) Composition
GB201403017D0 (en) Composition
ZA201704464B (en) Composition
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
IL270975A (en) Fast-acting insulin preparations
PT3217964T (pt) Composição
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201519442D0 (en) Composition
GB201404390D0 (en) Composition
ZA201606127B (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201402648D0 (en) Composition
IL250781A0 (en) preparation
GB201503484D0 (en) Composition
GB201502355D0 (en) Composition
GB201421660D0 (en) Composition